



































Dehydroepiandrosterone (DHEA) and its sulfated form 
(DHEAS), which will be referred to together as DHEA, 
are secreted by the zona reticularis of the adrenal cortex 
only in humans and related primate species [1].  DHEA 
is present in far higher concentrations in plasma than 
any other steroid hormone [1].  Adrenal production of 
DHEA begins during puberty, peaks at ~20 yr and 
begins to decline with aging beginning at ~25 yr [2,3].  
This decline is progressive and severe, resulting in a 
plasma DHEA level by age 75 yr that is ~80% lower 
than at 20 yr [2].  It has been reported that DHEA level 
predicts longevity in men [4].  Studies on laboratory 
rodents have shown that DHEA treatment reduces total 
and visceral fat accumulation and protects against 
development of muscle insulin resistance in response to 
a high fat diet [5,6], with advancing age [7], and in 
genetic obesity [8,9]. 
 
 


































In a preliminary study to test the hypothesis that, as in 
rodents, DHEA replacement reduces adiposity and 
improves insulin action, we evaluated the effects of six 
months of DHEA treatment (50 mg/day) in a 
randomized controlled trial on 56 elderly women and 
men [10].  The DHEA treatment induced significant 
decreases in abdominal fat and in the insulin area under 
the oral glucose tolerance curve, without a change in 
glucose levels, providing evidence for an increase in 
insulin sensitivity.  The present study was undertaken to 
determine whether a longer period of DHEA 
replacement improves both insulin action and glucose 




Study Participants   
Of the 659 people who initially expressed interest in the 



























randomized  double‐blind  study  was  to  determine  whether  a  longer  period  of  DHEA  replacement  improves  glucose
tolerance.  Fifty‐seven men and 68 women aged 65 to 75 yr were randomly assigned to 50 mg DHEA or placebo once daily.
Year one was a randomized, double blind trial.  Year 2 was an open label continuation.  DHEA replacement improved
glucose  tolerance  in  participants  who  had  abnormal  GT  initially,  reduced  plasma  triglycerides,  and  the  inflammatory
cytokines IL6 and TNFα.    
This trial was registered at clinicaltrials.gov as NCT00182975. 
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eligible volunteers were randomized to one year of 
DHEA replacement, 50 mg daily, or placebo.  After 
completing the 12 mo randomized study, 112 of the 
participants volunteered to continue in an open-label 
study for an additional 12 mo.  In the open-label study, 
the participants who had been randomized to DHEA 
replacement continued taking DHEA for a second year, 
while those who had been in the placebo group crossed 













































There were no significant differences between the 
DHEA and placebo groups in gender distribution, age 
or body mass index (BMI) (Table 1).  More of the 
participants in the placebo group were on anti-
dyslipidemic medications (Table 1).  Seventy-one 
percent of the participants in the DHEA group had 
abnormal oral glucose tolerance tests (2 hr glucose 
value above 140 mg/dl) initially compared to 52% of 






















































































Based on pill count, the percentage of prescribed doses 
taken averaged 94 ± 0.4% in the DHEA and 96 ± 0.4% 
in the placebo group. 
 
Physical Activity and Energy Intake 
Energy intake, estimated from food records, averaged 
2191 ± 62 kcal/day before and 2181 ± 67 kcal/day after 
12 mo of DHEA replacement, and 2116 ± 56 kcal/day 
before and 2151 ± 68 kcal/day after 12 mo in the 
placebo group. 
 
Body Weight and Composition 
The men in the DHEA group had a small but significant 
decrease in body weight during the first year of DHEA 
replacement, while the men in the placebo group gained 
weight (Table 2).  The DHEA replacement resulted in 
small but significant decreases in body fat percentage 





































men in the placebo group had small but significant 
increases (Table 2).  Trunk and appendicular fat masses 
showed a similar reduction (Table 2).  Abdominal 
visceral fat, evaluated using MRI, underwent a very 
small, but statistically significant, decrease in the men 
in the DHEA group; however, the difference between 
the changes in visceral fat between the DHEA and 
placebo groups was not significant (Table 2).  There 
were no significant changes in body weight in the 
women in either the DHEA or placebo group.  The only 
significant change in body composition in the women 
was a small increase in fat free mass in the DHEA 
group. 
 
During the second year of DHEA replacement, body 
weight, total fat mass and trunk and appendicular fat 
masses did not change significantly in the men (data not 
shown).  The men who crossed-over from placebo to 
DHEA had no significant changes in body weight or 
 
Table 1. Characteristics of the Participants  
  DHEA Placebo  Between Group 
P value 
Sex 
   Men 










Age, yr  70 ± 3  70 ± 3  0.84 
BMI, kg/m
2  28.4 ± 5.6  27.6 ± 4.9  0.40 
Medication use 
   Antidyslipidemic 












   Normal glucose tolerance 











History of cardiovascular disease  8   8   0.97 
Abbreviations: DHEA, dehydroepiandrosterone; BMI, body mass index 
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only change in body composition in the women who 
crossed over from placebo to 12 mo of DHEA was a 0.5 
± 0.2 kg (P<0.01) increase in fat free mass. 
 
Oral Glucose Tolerance Test 
One year of DHEA replacement resulted in significant 
decreases in the glucose values at the 60 min, 90 min 
and 120 min time points of the oral glucose tolerance 
test (OGTT) and in the glucose area under the curve 












































ment was seen in the participants in the placebo group 
who crossed over to DHEA in the second year open 
label study (data not shown).  Insulin levels during the 
OGTT tended to be lower after one year of DHEA 
replacement, but the decrease did not attain statistical 
significance (p=0.06 for change in area under the insulin 
curve) (Figure 2D).  However, the product of the glucose 
AUC and insulin AUC, an indicator of insulin resistance 
[11], was significantly improved, i.e. reduced, in 
response to one year of DHEA replacement (~22%, 
































































































It was evident on evaluation of the data, that 
improvements in glucose tolerance in response to 
DHEA occurred only in those participants who had 
abnormal glucose tolerance.  We, therefore, did a 
separate analysis on the glucose tolerance data of the 
participants who had abnormal glucose tolerance 
initially.  The improvements in glucose tolerance and 
AUC after one year (Figure 3C) of DHEA replacement 















































ed  by  the  values  obtained   on  the   participants  with  
normal glucose tolerance.  There were no significant 
changes in insulin levels during the OGTT except for 
the 120 min value, which was lower after 12 mo of 
DHEA (Figure 3D).  The improvements in glucose 
tolerance persisted during the additional 12 mo of open 
label DHEA replacement (Figure 3E).  There was no 
improvement in glucose tolerance in the participants 

















































The hormone data on most of the participants in this 
study have been reported previously in a paper 
describing the effects of the DHEA replacement on 
bone mineral density [12].  In both men and women, the 
DHEA replacement increased plasma DHEAS into the 
young normal range (men 68±7 to 371±23µg/dl; women 
41±5 to 293±21 µg/dl).  In the men, DHEA replacement 
resulted in small, but statistically significant increases in 
testosterone, estradiol and their free indexes (~12%, 
p<0.05).  In the women, testosterone and estradiol 
levels, and their free indexes increased about 2-fold in  
response to DHEA replacement. 
 
Plasma Lipids 
DHEA replacement resulted in a significant decrease in 







































mg/dl; Placebo: 103±8 mg/dl to 110±8 mg/dl; p<0.05 
within DHEA group; p<0.05 between groups).  There 
were no significant effects of DHEA on total, LDL, or 
HDL cholesterol in the men.  DHEA replacement 
resulted in a 9% decrease in HDL cholesterol in women 
(p<0.01).  This decrease had reversed by the end of the 
second year of DHEA replacement (initial 58±2, 12 mo 
53±2, 24 mo 56 ± 2 mg/dl, means ± SE).   
 
Inflammatory Cytokines 
There were significant decreases in the plasma 
concentrations of TNFα and IL-6 in response to 1 year 
of DHEA replacement (Table 3). 
 
Adverse Events 
There were 12 serious adverse events and 124 minor 
events, with no difference in frequency between groups.   
 
Table 2. Body Weight and Body Composition Before and After 12 months of DHEA  
   Men    Women 
  Group   Baseline 12  Mos 
Between-group 
  Baseline  12  Mos 
Between-group 
Difference P  Differenc
e  P 






84.5±2.2  -1.6±0.6 0.008      72.5±2.9 
75.1±3.0 
72.9±2.9 









25.9±1.2*  -1.3±0.4 0.001      39.1±1.1 
40.0±1.1 
38.7±1.1 
40.3±1.2  -0.7±0.4  0.09 






22.4±1.5*  -1.6±0.5 0.001      29.1±1.9 
30.9±2.0 
29.0±1.9 









62.1±1.1  -0.1±0.3 0.81      43.3±1.1 
44.2±1.2 
43.9±1.2* 
43.9±1.2  0.8±0.3  0.01 








12.3±0.9*  -0.9±0.3 0.009      14.1±0.9 
14.7±0.9 
14.0±0.9 









9.0±0.6  -0.7±0.2 0.0001      14.2±1.0 
15.3±1.1 
14.1±1.0 
15.4±1.1  -0.2±0.3 0.52 
VAT, cm






1765±214  -117±62 0.06      932±106 
906±92 
909±108 
895±90  -11±44 0.81 
SAT, cm





































There were no serious adverse events attributable to 
DHEA replacement.  Mild adverse events were 
development of acne in two women, which cleared up 
spontaneously, and increased facial hair growth in 
another woman.  PSA levels averaged 1.10 ± 0.13 mg/ml 
at baseline and 1.07 ± 0.12 mg/dl after 12 mo in the men 
on DHEA, and 0.95 ± 0.13 mg/dl at baseline and 0.98 ± 
0.12 mg/dl after 12 mo in the men in the placebo group.  
Based on mammograms and pap smears, no evidence of 
breast cancer or cervical abnormalities were detected in 
the women.  Serum markers of liver function were 




In our previous study, 6 mo of DHEA replacement 
resulted in an improvement in insulin action evidenced 
by a smaller increase in insulin during an OGTT 
without a change in glucose response [10].  In the 
present study, a longer period of DHEA replacement 
resulted not only in a reduction in insulin resistance, but 
also in improved glucose tolerance, in elderly, 
overweight or obese women and men with abnormal 
glucose tolerance.  The magnitude of this improvement 
was impressive, as DHEA replacement for 1 yr resulted 
in an 18 mg/dl decrease in the 2h glucose value of the 
OGTT (p,0.02 vs. placebo) and 2 yr of DHEA resulted 
in a 21 mg/dl in the 2h glucose value.  These findings 
have relevance to the current epidemic of impaired 
glucose tolerance and type 2 diabetes [13] because they 
raise the possibility that DHEA could be an effective 
treatment for impaired glucose tolerance and for 
prevention of type 2 diabetes. 
 
Visceral fat, measured by MRI, decreased ~10% in both 




















observation that DHEA protects laboratory rodents 
against visceral fat accumulation and insulin resistance 
with aging [7] and in response to high fat diets [5,6], led 
us to conclude that DHEA improves insulin action 
largely by reducing intra-abdominal fat [10].   
 
While the present results confirm that DHEA 
replacement decreases insulin resistance in individuals 
with abnormal glucose tolerance, they do not support 
our previous conclusion that this improvement is largely 
mediated by a decrease in visceral fat.  In the present 
study, the women had a small increase in fat free mass 
without a decrease in abdominal fat, while the men had 
only a small decrease in visceral fat in response to 
DHEA, suggesting that the reduction in visceral fat 
observed in our previous, 6 mo study is a transient 
effect. 
 
In addition to our earlier study [10], other studies have 
found an improvement in insulin action in response to 
DHEA replacement, including in hypoadrenal women 
[13], middle-aged hypercholesterolemic men [14], and 
postmenopausal women [15].  However, in contrast to 
the present results, it was recently reported by Nair et al. 
[16] and Basu et al. [17] that two years of DHEA 
treatment had no effect on insulin action or postprandial 
glucose turnover in elderly men and women.  The 
difference between the results of their study and ours, 
despite a similar study design, would be puzzling were 
it not for our finding that DHEA replacement improved 
glucose tolerance/insulin resistance only in those 
participants who had abnormal glucose tolerance, with 
no improvement in those with normal glucose tolerance.  
Although Nair et al. [16] and Basu, et al. [17] did not 
perform a standard OGTT, it appears that their subjects 
were unusually insulin sensitive for their age.  This is 
 
Table 3. Circulating Inflammatory Cytokines  





   Baseline 
   12 months 
   Change 
   Within group P value 
 
1.43 ± 0.13 
1.25 ± 0.09 
-0.18 ± 0.09 
0.18 
 
1.34 ± 0.16 
1.62 ± 0.22 












   Baseline 
   12 months 
   Change 
   Within group P value 
 
2.73 ± 0.20 
2.32 ± 0.15 
-0.41 ± 0.13 
0.004 
 
2.45 ± 0.16 
2.93 ± 0.17 













www.impactaging.com                   539                                             AGING,    May 2011, Vol.3 No.5evidenced by a fasting insulin level of ~3.6 µU/ml, a 
value similar to that of their young controls and about 
50% lower than that of our participants with abnormal 
glucose tolerance, a fasting glucose value ~5 mgdl 
lower than that of our participants, and a calculated 
HOMA index [18] of insulin resistance of 0.88 
compared to 1.88 for our participants with abnormal 
glucose tolerance.  Thus, the lack of effect of DHEA on 
insulin action in the study by Nair et al. [16] and Basu 
et al. [17] is in keeping with our finding that DHEA 
improves insulin action only in individuals with 
abnormal glucose tolerance. 
 
Regarding mechanisms by which DHEA may reverse 
insulin resistance, one possibility is by activation of 
PPARα for which DHEA is a ligand [19,20].  Activated 
PPARα stimulates expression of the mitochondrial 
enzymes involved in fat oxidation and represses 
activation of enzymes involved in fat synthesis[20,21].  
As a result, PPARα activation lowers triglycerides [21], 
and could result in less fat deposition in liver and 
muscle.  PPARα activation also suppresses inflame-
mation [21], and DHEA has been shown to inhibit 
nuclear factor Kappa B and production of IL-6 and 
TNFα by various cell types, and to lower circulating 
levels of these inflammatory cytokines [22-26].   
Chronic inflammation in adipose tissue and 
macrophages is thought to be one of the factors that 
mediates insulin resistance [27,28].  In the present 
study, DHEA replacement resulted in significant 
reductions in plasma IL-6 and TNFα, suggesting a 
decrease in inflammation.  It is of interest relative to a 
role of PPARα activation in the improvement in insulin 
action induced by DHEA, that fibrates, which mediate 
their effects on lipid metabolism by activating PPARα 
[21], have also been reported to improve insulin action 
and glucose tolerance [29-36]. 
 
Another mechanism by which DHEA or some of its 
metabolites might enhance insulin action is by 
improving impaired activation of phosphatidyl inositol 
3-kinase and Akt/PkB by insulin in insulin resistant 
muscle [37-39].  It is interesting in this regard that 17α-
ethynyl-5-androstene-3β, 7β, 17β triol, an analog of a 
DHEA metabolite, enhances insulin-stimulated 
Akt/PkB phosphorylation in muscle, and improves 
muscle and liver insulin sensitivity and glucose 
tolerance in Zucker diabetic rats and improves insulin 
sensitivity in insulin resistant humans [37]. 
 
In conclusion, the results of this study confirm our 
previous finding that DHEA replacement in elderly men 
and women improves insulin action [10].  They further 
show that a longer period of DHEA treatment than was 
evaluated in our previous study, 12 mo vs. 6 mo, also 
significantly improves glucose tolerance, and that this 
improvement occurs only in those individuals who have 
abnormal glucose tolerance.  These findings raise the 
possibility that DHEA could become a first line treatment 
for glucose intolerance/insulin resistance and diabetes 
prevention in older individuals and ameliorate the 




Participants.  Men and women, aged 65-75y were 
recruited from the Saint Louis area. Screening included 
a medical history, physical examination, blood 
chemistry analysis, hematology, urinalysis, and 
electrocardiography. Volunteers were excluded if they 
were current smokers or if they had evidence of chronic 
infection, a history or evidence of malignancy within 
the past 5 yr, clinical cardiovascular disease, advanced 
emphysema, advanced Parkinson’s disease, resting 
blood pressure >170 mmHg systolic or >100 mmHg 
diastolic, or diabetes (self-report or fasting plasma 
glucose ≥ 126 mg/dL). Participants taking medications 
were required to maintain stable dosing regimens for six 
months prior to the study. Informed written consent was 
obtained from the participants, and the study was 
approved by the Human Research Protection Office at 
Washington University School of Medicine. 
 
Intervention.  Participants were randomized to 12 
months of 50 mg/d DHEA or placebo. Both groups 
received multivitamin and calcium/vitamin D 
supplements and were advised to maintain their usual 
diet and physical activity. During monthly meetings 
with the study nurse, participants received a month’s 
supply of DHEA or placebo, had pill counts performed, 
and were questioned about adverse events, changes in 
activity level, diet, and medications. 
 
Oral Glucose Tolerance Test (OGTT).  OGTTs (75g) 
were started in the morning after an overnight fast. The 
study dietitian instructed the participants to consume ≥ 
250 g/day carbohydrate for the three days preceding the 
test.  Plasma glucose and insulin were measured using 
the glucose oxidase method (model 2300 Stat Plus, YSI 
Inc., Yellow Springs, Ohio) and radioimmunoassay 
[40].  Incremental area under the curve (AUC) was 
calculated for OGTT glucose and insulin values by the 
trapezoidal method [41].  Because of technical problems 
year 2 insulin data were not available. Although 
volunteers with self-reported diabetes or a fasting 
plasma glucose ≥126 mg/dL were excluded from the 
study, results from the baseline OGTT indicated that 16 
of the enrolled participants had diabetes based on a 2-hr 
glucose  ≥200 mg/dL.  These participants were not 
excluded. 
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HDL-cholesterol, and glycerol-blanked triglycerides 
(TGs) were measured by a CLIA-certified clinical 
laboratory using automated enzymatic/colorimetric 
assays (Roche/Hitachi Modular Analytics System; 
Roche Diagnostics Corporation, Indianapolis, IN). 
Tumor necrosis factor-α (TNFα) and interleukin-6 (IL-
6) (Quantikine High Sensitive, R&D Systems, 
Minneapolis, MN) were measured by using ELISA. 
 
Body Composition, Body Mass, and Height.  Whole 
body fat mass and fat free mass, Truncal fat and 
appendicular fat mass, were measured by dual X-ray 
absorptiometry (DXA) (Delphi W, software version 
11.2; Hologic Corporation, Waltham MA). Visceral and 
subcutaneous abdominal adipose tissue volumes were 
measured using magnetic resonance imaging. Ten serial 
10-mm axial images were acquired using a 1.5-T super-
conducting magnet (Siemens, Iselin, NJ), beginning at 
the first lumbar vertebra and moving downward. Images 
were batch analyzed with HIPPO software (version 1.3, 
Pisa, Italy) [42,43]. Slice level fat volumes were 
summed to get total adipose tissue volumes for the 
region of interest.  
 
Physical Activity.  Physical activity levels were 
assessed using the Aerobic Center Longitudinal Study 
Physical Activity Questionnaire [44]. The questionnaire 
is designed to assess habitual physical activity 
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